Liposomal Drug Delivery System for Ocular Application

Vivek Kumar Pandey[1], Neelima Goswami[2], Swati Rathore[3], Priyanka Rathore[4], R.B. Goswami[5]
[1,2,3,4,5]*Sagar Institute of Research Technology & Science-Pharmacy, Bhopal, Madhya Pradesh, India*

***Abstract*—Ocular drug delivery remains a major pharmaceutical challenge because the eye is protected by highly efficient anatomical, physiological, and biochemical barriers. Conventional eye drops are convenient and non-invasive, but their bioavailability is generally poor due to tear dilution, blinking, nasolacrimal drainage, corneal epithelial resistance, and short precorneal residence time. These limitations increase dosing frequency, reduce patient compliance, and may cause local or systemic adverse effects. Liposomal drug delivery systems offer an important nanocarrier-based strategy to overcome these problems. Liposomes are spherical phospholipid vesicles with an aqueous core and lipid bilayer, allowing incorporation of both hydrophilic and lipophilic drugs. Their similarity to biological membranes provides high biocompatibility, while their vesicular structure supports drug protection, sustained release, and improved interaction with ocular tissues. Surface-modified liposomes, especially cationic liposomes, are particularly useful for topical ocular delivery because they interact electrostatically with the negatively charged mucin and corneal surface. This article review soculardelivery barriers, liposomal formulation principles, preparation methods, characterization parameters, evaluation techniques, therapeutic applications, marketed lipid-based products, and future research directions. The discussion shows that liposomal ocular systems may be useful in glaucoma, dry eye disease, ocular infections, inflammation, age-related macular degeneration, and diabetic retinopathy. However, formulation stability, sterilization, manufacturing scale-up, regulatory requirements, and long-term safety must be addressed for broader clinical translation.[1,2,3]**

***Index Terms*—Liposomes, ocular drug delivery, nanocarriers, cationic liposomes, sustained release, corneal permeation, ophthalmic formulation.**

I. INTRODUCTION

The eye is a highly specialized organ with protective mechanisms designed to preserve vision and prevent entry of foreign substances. These mechanisms include the eyelids, tear film, corneal epithelium, conjunctiva, sclera, blood-aqueous barrier, blood-retinal barrier, metabolic enzymes, and active efflux transporters. Although these defenses are essential for ocular safety, they also restrict the entry of therapeutic agents. For this reason, ocular drug delivery is considered one of the most difficult areas of dosage form development.[1,2]

Topical eye drops remain the most commonly used dosage form for anterior segment disorders such as conjunctivitis, glaucoma, dry eye disease, keratitis, and anterior uveitis. However, after instillation, the formulation is rapidly diluted by tears and removed by blinking and nasolacrimal drainage. Only a small fraction of the applied dose is retained on the ocular surface for absorption. This short contact time leads to poor drug penetration and makes frequent administration necessary.[3]

Posterior segment disorders, including diabetic retinopathy, age-related macular degeneration, posterior uveitis, and retinal vascular diseases, are even more difficult to treat because drugs must cross additional barriers to reach the retina and vitreous. Intravitreal injection can deliver a high local concentration, but it is invasive and may be associated with endophthalmitis, hemorrhage, retinal detachment, pain, and repeated hospital visits. These limitations justify the search for controlled and targeted ocular drug delivery systems.[2,4]

Nanocarrier-based systems such as liposomes, niosomes, solid lipid nanoparticles, polymeric nanoparticles, nanoemulsions, and micelles have been investigated to improve ocular bioavailability. Among these, liposomes have received considerable attention because of their structural similarity to cell membranes, good biocompatibility, and ability to encapsulate chemically diverse drugs. Their use in ophthalmic delivery aims to prolong residence time,

reduce drug loss, protect the active ingredient, and provide sustained release at the site of action.[5,6]

II. BARRIERS TO OCULAR DRUG DELIVERY

The major dynamic barriers to topical ocular drug delivery are tear turnover, blinking, and nasolacrimal drainage. The normal tear volume and limited conjunctival sac capacity cannot retain the entire instilled dose. Excess liquid is quickly drained into the nasal cavity, causing drug loss and possible systemic absorption. Therefore, an effective topical formulation must resist wash-out and maintain contact with the corneal surface for a longer period.[3]

The cornea isc composed of the epithelium, stroma, and endothelium. The epithelium is lipophilic and contains tight junctions, making it a strong barrier to hydrophilic drugs. The stroma is hydrophilic and restricts highly lipophilic drugs. Consequently, a drug must possess balanced physicochemical properties or be incorporated into a carrier that can facilitate its passage through both lipophilic and hydrophilic layers.[2]

The blood-aqueous barrier and blood-retinal barrier regulate the entry of substances into the aqueous humor and retina. These barriers make systemic therapy inefficient for many ocular disorders because high systemic doses may be required to achieve therapeutic ocular concentrations. In addition, ocular enzymes may degrade susceptible molecules, while efflux transporters such as P-glycoprotein may reduce intracellular drug accumulation. Liposomal encapsulation can provide partial protection against enzymatic degradation and may improve tissue deposition.[2,5]

III. LIPOSOMAL DRUG DELIVERY SYSTEM

Liposomes are microscopic vesicles composed mainly of phospholipids arranged in one or more concentric bilayers surrounding an aqueous compartment. The amphiphilic nature. Hydrophilicdrugsare generally entrapped in the aqueous core, whereas lipophilic drugs areincorporated within the lipid bilayer. This dual loading capacity makes liposomes versatile carriers for many ophthalmic therapeutic agents.[6]

Liposomes may be classified as small unilamellar vesicles, large unilamellar vesicles, or multi lamel larvesicles depending on size and lamellarity. Forocular delivery, vesiclesizeand distribution are critical. Smaller and uniform liposomes are generally preferred because they provide better corneal interaction, improved physical stability, and lower irritation. Multilamellar vesicles, because of multiple lipid barriers, may provide slower drug release and longer therapeutic action.[6,7]

The most important advantage of liposomes in ophthalmic delivery is their ability to act as a drug reservoir. After administration, liposomes may adhere to the ocular surface and gradually release the drug, maintaining a therapeutic concentration for a longer time than conventional solutions. Encapsulation may also reduce irritation caused by high free-drug concentration and may improve the solubility of poorly soluble drugs.[5,8]

Cationic liposomes are particularly valuable for anterior ocular delivery. The corneal and mucin surfaces are negatively charged, so positively charged liposomes interact electrostaticallywiththem. The diffusion window for drug absorption. Cationic lipids such as stearylamine can also improve entrapment of anionic drugs through ionic interaction, supporting both higher drug loading and sustained release.[8,9]

IV. FORMULATION APPROACH

The design of ocular liposomes requires careful selection of lipid, cholesterol, charge inducer, aqueous phase, and manufacturing method. Phospholipids such as hydrogenated soybean phosphatidylcholine are often selected because saturated lipids create rigid bilayers and reduce leakage. Cholesterol is incorporated to stabilize the membrane, decrease bilayer fluidity, and improve storage stability.[7,8]

Charge modifiers are used to adjust zeta potential and biological interaction. For topical application, a positive surface charge is generally desirable because it improves mucoadhesion. The hydration medium should be compatible with the eye and adjusted near physiological pH and osmolarity. Phosphate buffer saline or simulated tear fluid can be used to maintain ocular acceptability during formulation and release testing.[8]

film is hydrated with an aqueous medium. The crude vesicles are then reduced in size using sonication,

extrusion, or homogenization. Although simple, this method may showlimitations such as broad size distribution and scale-up difficulty.[6]

Advanced techniques such as high-pressure homogenization and microfluidic homogenization are more suitable for reproducible production. These methods apply shear, turbulence. Such techniques are important for commercial development because particle size, polydispersity, entrapment efficiency, and sterility must remain consistent between batches.[10]

V. CHARACTERIZATION AND EVALUATION

A liposomal ocular formulation must be characterized for particle size, polydispersity index, zeta potential, entrapment efficiency, morphology, pH, osmolarity, viscosity, and stability. Particle size is commonly measured by dynamic light scattering. A low polydispersity index indicates a narrow size distribution and supports reproducible behavior. Zeta potential helps predict physical stability and confirms whether the vesicles possess the desired cationic surface charge.[10,11]

Entrapment efficiency indicates the percentageof drug in corporatedintothevesi les. Itis usually determined by separating free drug from liposome-associated drug through ultracentrifugation, dialysis, or filtration, followed by analytical quantification. Transmission electron microscopy or cryo-transmission electron microscopy may be used to examine vesicle shape, bilayer integrity, and lamellarity.[11]

In vitro release studies are performed in simulated tear fluid or appropriate buffer at ocular temperature. The aim is to determine whether the drug is released immediately, gradually, or in a controlled manner. Release data may be fitted to zero-order, first-order, Higuchi, or Korsmeyer-Peppas models. A sustained or near zero-order release pattern is desirable for reducing dosing frequency.[12]

Ex vivo transcorneal permeation studies using excised cornea mounted on Franzdiffusion cells are useful for comparing liposomal formulations with free drug solution or marketed products. Important parameters include cumulative permeation, steady-state flux, permeability coefficient, and permeation enhancement ratio. Safety assessment is equally important, and in vitro irritation assays, reconstructed corneal models, and cell viability studies can reduce dependence on conventional animal irritation tests.[8,13]

Table1.Key quality attributes of ocular liposomal formulations

Qualityattribute	Importance	Commonmethod
Particlesize andPDI	Controlspermeation,stability,and reproducibility	Dynamiclightscattering
Zetapotential	Predictscolloidalstabilityand mucoadhesion	Electrophoreticlightscattering
Entrapment efficiency	Indicatesdrugloadingand economic feasibility	SeparationfollowedbyHPLCorUV analysis
Morphology	Confirmsvesicleshapeand bilayer integrity	TEMorcryo-TEM
Releaseprofile	Showssustainedorcontrolled drug delivery	DialysisorFranzdiffusioncell

VI. THERAPEUTIC APPLICATIONS

In glaucoma, liposomal systems can prolong the ocular action of antiglaucoma drugssuch as pilocarpine, acetazolamide, timolol, or prostaglandin analogues. Sustained releaseand improved retention may reduce dosing frequency, improve patient adherence, and maintain more stable intraocular pressure control. This is important because glaucoma treatment is usually long term and compliance strongly influences disease progression.[8,14]

For ocular infections, liposomes can improve the delivery of antiviral, antibacterial, and antifungal drugs. Ganciclovir-loaded liposomes have shown improved ocular tissue concentrations compared with free drug, while liposomal antifungal formulations. These findings suggest that liposomes may help achieve local therapeutic levels while reducing toxicity.[12,15]

Dry eye disease is another important field for liposomal products. The disorder is often associated with tear film instability and lipid layer deficiency. Lipid-based eye drops and sprays containing phospholipids can restore or support the tear film

lipid layer, reduce evaporation. Drug liposomal eye drops may additionally treat inflammation associated with dry eye disease.[5,16]

For posterior segment diseases such as age-related macular degeneration and diabetic retinopathy, liposomes may act as intravitreal depot systems. Encapsulation of anti-vascular endothelial growth factor agents or other retinal drugs can extend drug residence within the vitreous and reduce the need for repeated injections. This has potential to reduce treatment burden and lower the cumulative risk of injection-related complications.[4,17]

VII. MARKETED PRODUCTS AND FUTURE PROSPECTS

The clinical feasibility of lipid-based ocular delivery is supported by marketed products. Visudyne, a verteporfin liposomal formulation used in photodynamic therapy, represents an important example of successful ocular liposom a technology. Several lipidor liposome-based products are also available for dry eye disease and ocular surface protection, including formulations that support the tear film lipid layer.[18]

Despite these advances, wider commercialization of liposomal ocular systems is restricted by technical challenges. Liposomes are complex colloidal systems that may undergo aggregation, fusion, oxidation, hydrolysis, and drug leakage during storage. Ophthalmic products must also be sterile and non-irritating. Therefore, formulation scientists must optimize lipid composition, cholesterol level, charge, particle size, preservative strategy, sterilization method, and packaging.[14]

Future research is moving toward targeted, hybrid, and stimuli-responsive liposomes. PEGylated or stealth liposomes may extend intravitreal residence by reducing biological clearance. Chitosan-coated liposomes may improve topical mucoadhesion and corneal penetration. Liposomal hydrogels can combine vesicular drug loading with gel-based retention. Ligand-functionalized liposomes may target retinal or inflammatory receptors, thereby increasing site-specific drug delivery.[14,17]

Computational optimization, design of experiments, and artificial neural networks can further improve formulation development by predicting the relationship between lipid composition, process variables, and product performance. Such approaches can reduce experimental burden and improve reproducibility. In the coming years, integration of nanotechnology with advanced manufacturing is expected to support the development of safer, longer acting, and patient-friendly ophthalmic formulations.[19]

VIII. CONCLUSION

Liposomal drug delivery systems provide a promising approach for overcoming the limitations of conventional ocular dosage forms. Their biocompatible phospholipid structure, ability to encapsulate hydrophilic and lipophilic drugs, sustained-release capacity, and potential for surface modification make them highly suitable for ophthalmic use. Cationic liposomes are especially effective for topical delivery because they interact with the negatively charged ocular surface and improve precorneal residence time.[5,8]

The available evidence indicates that liposomes can enhance drug retention, improve trans corneal permeation, protect drugs from degradation, and reduce dosing frequency. They have potential applications in glaucoma, dry eye disease, ocular infections, inflammation, age-related macular degeneration, and diabetic retinopathy. However, successful clinical translation requires careful control of stability, sterility, safety, manufacturing scale-up, and regulatory quality standards. With continued progress in formulation design and nanotechnology, liposomal ocular systems are likely to become increasingly important in modern ophthalmic therapy.[14,17]

ACKNOWLEDGEMENT

The authors express their sincere gratitude to Sagar Institute of Research Technology & Science-Pharmacy, Bhopal, for providing academic support, guidance, and encouragement during the preparation of this research article. The authors also acknowledge the valuable assistance of faculty members, colleagues, and all individuals who directly or indirectly contributed to the completion of this work.

REFERENCES

[1] Nagarwal RC, Kant S, Singh PN, Maiti P. Polymeric nanocarriers for ocular delivery. J Control Release. 2011;156(1):2-11.

[2] Cholkar K, Dasari SR, Pal D, Mitra AK. Eye: anatomy, physiology and barriers to drug delivery. In: Ocular transporters and receptors. New York: Elsevier; 2013.

[3] Qiao C, Zheng X, Yan H, Zhang W, Jiang Y. Ocular delivery of rebamipide liposomal eye drops: formulation optimization and in vitro/in vivo evaluation. Pharmaceutics. 2022;14(4):511.

[4] Gao H, Pennesi ME, Shah K, Qiao X, Hariprasad SM, Mieler WF, et al. Intravitreal sustained-release liposomes and posterior segment drug delivery. Invest Ophthalmol Vis Sci. 2012;53(11):7163-7169.

[5] Negi P, Aggarwal G, Sharma D. Liposomes: the versatile carrier for targeted drug delivery. J Drug Deliv Ther. 2019;9(2-s):403-410.

[6] BanghamAD, StandishMM, WatkinsJC.Diffusion of univalention sacross the lamellae of swollen phospholipids. J Mol Biol. 1965;13(1):238-252.

[7] KaurIP, KanwarM.Ocularpreparations: theformulationapproach. DrugDevIndPharm.2002;28(5):473-493.

[8] GuptaH,AqilM,KharRK,AliA,BhatnagarA, MittalG.Biodegradablelevofloxacin nanoparticles for sustained ocular drug delivery. J Drug Target. 2011;19(6):409-417.

[9] Monem AS, Ali FM, Ismail MW. Prolonged effect of liposomes encapsulating pilocarpine HCl in normal and glaucomatous rabbits. Int J Pharm. 2000;198(1):29-38.

[10] LiM,LiY,ChenJ, LiuY.High-pressure microfluidichomogenization for preparation of nanoliposomes: process control and stability. Pharmaceutics. 2023;15:1-15.

[11] VolianiV.Imaging of liposomes by transmission electronmicroscopy. MethodsMolBiol. 2023; 2575:299-309.

[12] Sanap U, Wagh P, Bhalerao V, Ghuge P. Development and evaluation of liposomal fluconazole for topical ophthalmic drug delivery. Pharmaceutics. 2024;16(10):1325.

[13] vanderMeerA, WientjesH,vanderMeiD.Aliposome-basedassayforestimatingocular toxicity of surfactants. Invest Ophthalmol Vis Sci. 2005;46(8):2824-2829.

[14] VermaniK, GargS.Intravitreallіposomes: areviewofcurrentresearchandfutureprospects. Drug Discov Today. 2012;17(1-2):50-66.

[15] Thrimawithana TR, Young SA, Rupenthal ID. Delivery of ganciclovir to the posterior eye via the transscleral route using liposomes. J Pharm Sci. 2011;100(12):5245-5254.

[16] El-Say KM, Ahmed OAA, Badr-Eldin SM. Liposomal formulations for ocular therapy and dryeye management. Int J Pharm. 2014;460(1-2):1-12.

[17] Vermani K, Garg S. Intravitreal liposomal drug delivery: opportunities for anti-VEGF and retinal therapy. Drug Discov Today. 2012;17(1-2):50-66.

[18] Bausch+Lomb.Visudyne(verteporfin)prescr ibing information. Bridgewater,NJ:Bausch+ Lomb; 2022.

[19] AkkaraJ, etal. Artificial neural network and Box-Behnken design for optimization of ganciclovir-loaded ocular liposomes. Pharm Dev Technol. 2015;20(5):1-9.